Module 1: Overview of the immune system; Cancer and immunity; Overview of immunotherapy; Patient population, limitations and benefits; Current research and trials.
Our new immunotherapies course is designed to support you to understand the role of immunotherapies in the treatment of cancer, and way this emerging treatment modality impacts your patients.
Module 1 is now available and we’re pleased to share our plans for the staged release of the course.
View the course →
Subject matter expert: Developing the immunotherapies course – Helen Westman
“I am the Immuno-Oncology and Lung Cancer Care Coordinator at Royal North Shore Hospital. I have been involved with eviQ education programs for a number of years as a facilitator for the ADAC program, and I am very excited to be involved in the development of nursing education and assessment resources for immunotherapy.
The use of immunotherapy has become standard of care in the treatment of melanoma and lung cancer and is set to increase rapidly with many patients likely to receive an immune checkpoint inhibitor at some stage during their illness. Currently, services are structured around chemotherapy delivery and knowledge gaps exist for nurses in the management of patients on immunotherapy and the unique spectrum of toxicities that it can cause. That is why the development of these resources has been so important.
The eviQ ADAC resource provided standardised evidence based information for nurses in chemotherapy delivery and the development of these new immunotherapy resources will provide the same platform for nurses involved in immunotherapy delivery. The challenge faced by the Clinical Advisory Committee and the eviQ team has been how to communicate complex and difficult concepts to a wide nursing audience. Through collaboration the end result are modules which are clear, interactive and easy to use and which will successfully deliver key concepts on immunotherapies and their side effects regardless of prior knowledge levels”.
Re-release: Central Venous Access Devices (CVAD)
3 x modules: Principals of Central Venous Access Devices; Patient assessment and education; Care and management of Central Venous Access Devices.
We’ve made some improvements using the feedback from our module survey including:
• Separating the module into smaller parts and activities
• Adding images and learning activities to enhance understanding
• Including a glossary for abbreviations
View the course →
Online discussion forum
We’ve had lots of requests for a safe space for facilitators to network, share information, ask questions and seek advice from each other – so we have launched a new discussion forum feature to support your networking needs.
The forum is restricted to facilitators only, so get to know your community and start a conversation!
Visit your online forum →
Facilitators forum - RSVP now!
We are still accepting RSVPs for the first eviQ Education face to face facilitator’s forum! The forum will take place on the 21 June 2018 at the Rydges South Bank Brisbane.
The program will run from 12.30pm – 6pm and will include a session workshopping the upcoming review of ADAC to ensure the new version best reflects your needs. The session will also feature an update on new resources, new ways of learning, a guest speaker and networking drinks.
We are no longer accepting flight requests. Those who submitted their requests will be contacted shortly by our booking team. RSVPs are still open for all other attendees, including those wishing to videoconference.
The team is looking forward to meeting you all in Brisbane!
RSVP now →
Hello from ASMIRT!
Lisa McLean represented the team at the peak radiation therapists meeting in Canberra this month.
We’re excited to start exploring the development of radiation therapy learning resources and welcome your involvement!
Join a radiation therapy review group →
eviQ is recruiting!
The eviQ team is recruiting a permanent full-time content author (haematology nursing). eviQ content authors are responsible for the development of new eviQ content and periodic review of all existing eviQ content, ensuring that eviQ provides current and accurate evidence-based point-of-care cancer treatment information to cancer clinicians, patients and their carers for the Australian clinical context. eviQ content authors work closely with external clinicians, coordinating and facilitating eviQ Reference Committee meetings where clinicians discuss and debate eviQ content for approval and review and consensus must be reached.
If you have excellent clinical cancer skills and work well with clinical stakeholders, we need you!
This role is based at the Cancer Institute Eveleigh, Sydney, NSW. Applications close 15 April 2018.
Apply online →
Reviewers needed – Febrile Neutropenia (adult and paediatric): We are still recruiting for our febrile neutropenia review groups. Register now to lend your expertise to either the adult or paediatric groups: Febrile neutropenia review group
eviQ Education flyers available for your practice! Featuring a catalogue of all our courses. Request hardcopies by emailing us your details: firstname.lastname@example.org
Facilitator training (online webinar): Register for our next online facilitator training on Wednesday 18 April 2018 from 11:30-1:30pm (EST). Please email us on email@example.com to book your place and receive webinar login details.
Share the love: If you have a colleague who may be interested in receiving this newsletter – please invite them to subscribe!
Feedback please: We would love to hear what you think about this newsletter – so please drop us a line with any story ideas, requested content or to volunteer you learnings as a case study: firstname.lastname@example.org
Keep your LMS up to date
Each time we update a course we will let you know – but please be sure to reload the scorm files into your LMS to make sure your users have access to the most accurate information!
Did you know?
Did you know the concept of immunotherapy was originated in 1890? Bacterial toxins were administered to patients as a cancer vaccine and was shown to have some benefit.
Learn more about immunotherapy →
Having trouble reading this update? View our online version here